{"pmid":32360695,"pmcid":"PMC7190510","title":"Comment on \"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?\"","text":["Comment on \"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?\"","Diabetes Res Clin Pract","Cure, Erkan","Cumhur Cure, Medine","32360695"],"journal":"Diabetes Res Clin Pract","authors":["Cure, Erkan","Cumhur Cure, Medine"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360695","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.diabres.2020.108184","keywords":["angiotensin-converting enzyme 2","covid-19, t2dm","dapagliflozin","diabetes mellitus","insulin","metformin"],"weight":0,"_version_":1666138495533449216,"score":9.490897,"similar":[{"pmid":32387329,"title":"Reply to Comment on \"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?\"","text":["Reply to Comment on \"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?\"","Diabetes Res Clin Pract","Pal, Rimesh","Bhadada, Sanjay K","32387329"],"journal":"Diabetes Res Clin Pract","authors":["Pal, Rimesh","Bhadada, Sanjay K"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387329","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108192","keywords":["angiotensin-converting enzyme 2","anti-diabetic medications","covid-19","insulin"],"weight":0,"_version_":1666428892692348928,"score":137.32394},{"pmid":32283128,"pmcid":"PMC7151403","title":"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","text":["Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","Diabetes Res Clin Pract","Pal, Rimesh","Bhadada, Sanjay K","32283128"],"journal":"Diabetes Res Clin Pract","authors":["Pal, Rimesh","Bhadada, Sanjay K"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283128","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.diabres.2020.108146","keywords":["angiotensin-converting enzyme 2","covid-19","diabetes mellitus","t2dm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491500625920,"score":119.37548},{"pmid":32382358,"pmcid":"PMC7204191","title":"COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","text":["COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?","Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.","Diabetes Ther","Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos","32382358"],"abstract":["Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses."],"journal":"Diabetes Ther","authors":["Penlioglou, Theano","Papachristou, Stella","Papanas, Nikolaos"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382358","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s13300-020-00830-0","keywords":["antidiabetic agents","corona virus infectious disease","diabetes mellitus","metformin","pioglitazone","treatment"],"e_drugs":["Pioglitazone","Metformin"],"topics":["Treatment"],"weight":1,"_version_":1666419683255910400,"score":83.03744},{"pmid":32220179,"title":"[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","text":["[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.","Sichuan Da Xue Xue Bao Yi Xue Ban","Ma, Wan-Xia","Ran, Xing-Wu","32220179"],"abstract":["Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients."],"journal":"Sichuan Da Xue Xue Bao Yi Xue Ban","authors":["Ma, Wan-Xia","Ran, Xing-Wu"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220179","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.12182/20200360606","keywords":["blood glucose level","blood glucose monitoring","coronavirus disease 2019, covid-19","diabetes mellitus","inpatient glycemic control","insulin","therapy"],"e_drugs":["Glucose"],"topics":["Treatment"],"weight":1,"_version_":1666138492311175168,"score":61.080765},{"pmid":32334502,"title":"The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","text":["The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge.","Curr Neurovasc Res","Maiese, Kenneth","32334502"],"abstract":["Multiple viral pathogens can pose a significant health risk to individuals. As a recent example, the beta-coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical to address this global concern. One such avenue that may prove to be exceedingly fruitful and offer exciting potential as new antiviral therapy involves the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), and AMP activated protein kinase (AMPK). Recent work has shown that mTOR pathways in conjunction with AMPK may offer valuable targets to control cell injury, oxidative stress, mitochondrial dysfunction, and the onset of hyperinflammation, a significant disability associated with COVID-19. Furthermore, pathways that can activate mTOR may be necessary for anti-hepatitis C activity, reduction of influenza A virus replication, and vital for type-1 interferon responses with influenza vaccination. Yet, important considerations for the development of safe and effective antiviral therapy with mTOR pathways exist. Under some conditions, mTOR can act as a double edge sword and participate in virion replication and virion release from cells. Future work with mTOR as a potential antiviral target is highly warranted and with a greater understanding of this novel pathway, new treatments against several viral pathogens may successfully emerge."],"journal":"Curr Neurovasc Res","authors":["Maiese, Kenneth"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334502","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.2174/1567202617666200425205122","keywords":["amp activated protein kinase (ampk)","akt","covid-19","sars-cov-2","angiotensin converting enzyme 2","apoptosis","autophagy","coronaviruses","cytokines","diabetes mellitus","inflammation","influenza","interferons","interleukins","mtor complex 1 (mtorc1)","mtor complex 2 (mtorc2)","macrophage inflammatory protein 1-alpha (mip-1alpha)","mechanistic target of rapamycin (mtor)","metformin","monocyte chemoattractant protein 1 (mcp-1)","oxidative stress","tumor necrosis factor-alpha","virion"],"locations":["Rapamycin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494085365762,"score":59.605976}]}